Apremilast
Apremilast is an inhibitor of phosphodiesterase 4 (PDE4) that is clinically used to treat psoriasis and psoriatic arthritis. Apremilast exhibits anti-inflammatory and immunomodulatory activities, increasing levels of cAMP and IL-10 and decreasing levels of iNOS, IL-23, and TNF-α in vitro and in vivo.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1884198
| Cas No. |
608141-41-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C23H25NO7S |
| Formula Wt. |
459.51 |
| IUPAC Name |
N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide |
| Appearance |
White to off white powder |
Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014 Sep;26(9):2016-29. PMID: 24882690.
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. PMID: 22257911.
